作者: Muhammed Murtaza , Sarah-Jane Dawson , Katherine Pogrebniak , Oscar M Rueda , Elena Provenzano
DOI: 10.1038/NCOMMS9760
关键词:
摘要: Circulating tumour DNA analysis can be used to track burden and analyse cancer genomes non-invasively but the extent which it represents metastatic heterogeneity is unknown. Here we follow a patient with ER-positive HER2-positive breast receiving two lines of targeted therapy over 3 years. We characterize genomic architecture infer clonal evolution in eight biopsies nine plasma samples collected 1,193 days clinical follow-up using exome amplicon sequencing. Mutation levels reflect hierarchy inferred from sequencing biopsies. Serial changes circulating sub-clonal private mutations correlate different treatment responses between sites. This comparison biopsy single shows that allow real-time sampling multifocal evolution.